1. Home
  2. KNSL vs ABVX Comparison

KNSL vs ABVX Comparison

Compare KNSL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kinsale Capital Group Inc.

KNSL

Kinsale Capital Group Inc.

HOLD

Current Price

$373.18

Market Cap

9.2B

Sector

Finance

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$109.76

Market Cap

10.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNSL
ABVX
Founded
2009
2013
Country
United States
France
Employees
N/A
67
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.2B
10.5B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
KNSL
ABVX
Price
$373.18
$109.76
Analyst Decision
Buy
Buy
Analyst Count
10
12
Target Price
$455.40
$128.42
AVG Volume (30 Days)
261.3K
714.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.26%
N/A
EPS Growth
21.77
N/A
EPS
21.65
N/A
Revenue
$1,873,987,000.00
N/A
Revenue This Year
$6.46
N/A
Revenue Next Year
$8.77
$0.22
P/E Ratio
$17.53
N/A
Revenue Growth
18.04
N/A
52 Week Low
$341.06
$4.77
52 Week High
$512.76
$148.83

Technical Indicators

Market Signals
Indicator
KNSL
ABVX
Relative Strength Index (RSI) 42.10 38.48
Support Level $365.55 $107.99
Resistance Level $402.61 $131.27
Average True Range (ATR) 10.96 5.11
MACD -0.19 -1.73
Stochastic Oscillator 17.54 14.40

Price Performance

Historical Comparison
KNSL
ABVX

About KNSL Kinsale Capital Group Inc.

Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: